Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Monkhorst

Showing results (151-160 of 160) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 160 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2023
Elucidating the Heterogeneity of Immunotherapy Response and Immune-Related Toxicities by Longitudinal ctDNA and Immune Cell Compartment Tracking in Lung CancerJoseph C Murray, Lavanya Sivapalan, Karlijn Hummelink, et al.
Nature Cancer|September 28, 2020
Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancerValsamo Anagnostou, Noushin Niknafs, Kristen Marrone, et al.
Nature Protocols|December 13, 2023
Optimized whole-genome sequencing workflow for tumor diagnostics in routine pathology practiceKris G Samsom, Linda J W Bosch, Luuk J Schipper, et al.
Lung Cancer (Amsterdam, Netherlands)|October 3, 2025
Determining the optimal approach to identify osimertinib resistance; the first line osimertinib cohort of the OSIRIS studyJ W T van der Wel, S M Ernst, M Jebbink, et al.
Lung Cancer (Amsterdam, Netherlands)|October 21, 2019
ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinibE Thunnissen, B I Lissenberg-Witte, M M van den Heuvel, et al.
JCO Precision Oncology|September 11, 2020
Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung CancerSebastian Michels, Carina Heydt, Bianca van Veggel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 30, 2017
Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape ProjectK M Kerr, U Dafni, K Schulze, et al.
The Oncologist|October 28, 2020
Multicenter Comparison of Molecular Tumor Boards in The Netherlands: Definition, Composition, Methods, and Targeted Therapy RecommendationsBart Koopman, Harry J M Groen, Marjolijn J L Ligtenberg, et al.
Cancer Immunology Research|April 4, 2024
The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer ImmunotherapyMichael V Martin, Salvador Aguilar-Rosas, Katka Franke, et al.
Nature Communications|April 12, 2025
Generation of field-reversed configurations via neutral beam injectionT Roche, S Dettrick, A Fontanilla, et al.
Pageof 16

Showing results (151-160 of 160) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 160 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2023
Elucidating the Heterogeneity of Immunotherapy Response and Immune-Related Toxicities by Longitudinal ctDNA and Immune Cell Compartment Tracking in Lung CancerJoseph C Murray, Lavanya Sivapalan, Karlijn Hummelink, et al.
Nature Cancer|September 28, 2020
Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancerValsamo Anagnostou, Noushin Niknafs, Kristen Marrone, et al.
Nature Protocols|December 13, 2023
Optimized whole-genome sequencing workflow for tumor diagnostics in routine pathology practiceKris G Samsom, Linda J W Bosch, Luuk J Schipper, et al.
Lung Cancer (Amsterdam, Netherlands)|October 3, 2025
Determining the optimal approach to identify osimertinib resistance; the first line osimertinib cohort of the OSIRIS studyJ W T van der Wel, S M Ernst, M Jebbink, et al.
Lung Cancer (Amsterdam, Netherlands)|October 21, 2019
ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinibE Thunnissen, B I Lissenberg-Witte, M M van den Heuvel, et al.
JCO Precision Oncology|September 11, 2020
Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung CancerSebastian Michels, Carina Heydt, Bianca van Veggel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 30, 2017
Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape ProjectK M Kerr, U Dafni, K Schulze, et al.
The Oncologist|October 28, 2020
Multicenter Comparison of Molecular Tumor Boards in The Netherlands: Definition, Composition, Methods, and Targeted Therapy RecommendationsBart Koopman, Harry J M Groen, Marjolijn J L Ligtenberg, et al.
Cancer Immunology Research|April 4, 2024
The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer ImmunotherapyMichael V Martin, Salvador Aguilar-Rosas, Katka Franke, et al.
Nature Communications|April 12, 2025
Generation of field-reversed configurations via neutral beam injectionT Roche, S Dettrick, A Fontanilla, et al.
Pageof 16